Provention Bio Stock Forecast, Price & News

Provention Bio (NASDAQ:PRVB) Frequently Asked Questions

Is Provention Bio a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Provention Bio in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Provention Bio stock.
View analyst ratings for Provention Bio or view top-rated stocks.

How has Provention Bio's stock price been impacted by Coronavirus (COVID-19)?

Provention Bio's stock was trading at $9.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PRVB stock has decreased by 28.4% and is now trading at $6.45.
View which stocks have been most impacted by COVID-19.

When is Provention Bio's next earnings date?

Provention Bio is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Provention Bio.

How were Provention Bio's earnings last quarter?

Provention Bio, Inc. (NASDAQ:PRVB) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.08. The company earned $0.68 million during the quarter, compared to analyst estimates of $3.75 million. During the same quarter in the prior year, the company earned ($0.56) earnings per share.
View Provention Bio's earnings history.

What price target have analysts set for PRVB?

8 analysts have issued 1-year price objectives for Provention Bio's shares. Their forecasts range from $8.00 to $25.00. On average, they expect Provention Bio's share price to reach $17.75 in the next twelve months. This suggests a possible upside of 175.2% from the stock's current price.
View analysts' price targets for Provention Bio or view top-rated stocks among Wall Street analysts.

Who are Provention Bio's key executives?

Provention Bio's management team includes the following people:

• Ashleigh W. Palmer, Chief Executive Officer & Director
• Eleanor Leni Ramos, Chief Operating & Medical Officer
• Andrew T. Drechsler, Chief Financial Officer
• Francisco Leon, Chief Scientific Officer
• Alex Rabiee, Vice President-Business Development

Who are some of Provention Bio's key competitors?

Some companies that are related to Provention Bio include Supernus Pharmaceuticals (SUPN), IGM Biosciences (IGMS), ADC Therapeutics (ADCT), Protagonist Therapeutics (PTGX), Verve Therapeutics (VERV), Rocket Pharmaceuticals (RCKT), ImmunoGen (IMGN), Madrigal Pharmaceuticals (MDGL), Amarin (AMRN), NGM Biopharmaceuticals (NGM), Myovant Sciences (MYOV), MorphoSys (MOR), COMPASS Pathways (CMPS), Xenon Pharmaceuticals (XENE) and FibroGen (FGEN).
View all of PRVB's competitors.

What other stocks do shareholders of Provention Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Provention Bio investors own include NVIDIA (NVDA), OPKO Health (OPK), Amarin (AMRN), QUALCOMM (QCOM), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Axsome Therapeutics (AXSM), Fulcrum Therapeutics (FULC) and AbbVie (ABBV).

What is Provention Bio's stock symbol?

Provention Bio trades on the NASDAQ under the ticker symbol "PRVB."

Who are Provention Bio's major shareholders?

Provention Bio's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.09%), Geode Capital Management LLC (1.64%), Millennium Management LLC (1.24%), Verition Fund Management LLC (1.13%), DG Capital Management LLC (0.86%) and Rice Hall James & Associates LLC (0.38%). Company insiders that own Provention Bio stock include Andrew T Drechsler, Ashleigh Palmer, Eleanor Ramos, Francisco Leon and Jason Hoitt.
View institutional ownership trends for Provention Bio.

Which major investors are selling Provention Bio stock?

PRVB stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Goldman Sachs Group Inc., 683 Capital Management LLC, BlackRock Inc., Jane Street Group LLC, New York State Common Retirement Fund, Wolverine Trading LLC, and California State Teachers Retirement System.
View insider buying and selling activity for Provention Bio or view top insider-selling stocks.

Which major investors are buying Provention Bio stock?

PRVB stock was bought by a variety of institutional investors in the last quarter, including Verition Fund Management LLC, DG Capital Management LLC, Millennium Management LLC, Geode Capital Management LLC, Barclays PLC, Two Sigma Investments LP, Morgan Stanley, and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have bought Provention Bio stock in the last two years include Andrew T Drechsler, Ashleigh Palmer, Eleanor Ramos, Francisco Leon, and Jason Hoitt.
View insider buying and selling activity for Provention Bio or or view top insider-buying stocks.

How do I buy shares of Provention Bio?

Shares of PRVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Provention Bio's stock price today?

One share of PRVB stock can currently be purchased for approximately $6.45.

How much money does Provention Bio make?

Provention Bio has a market capitalization of $408.77 million. The company earns $-98.58 million in net income (profit) each year or ($1.99) on an earnings per share basis.

How many employees does Provention Bio have?

Provention Bio employs 59 workers across the globe.

What is Provention Bio's official website?

The official website for Provention Bio is www.proventionbio.com.

Where are Provention Bio's headquarters?

Provention Bio is headquartered at P.O. BOX 666, OLDWICK NJ, 08858.

How can I contact Provention Bio?

Provention Bio's mailing address is P.O. BOX 666, OLDWICK NJ, 08858. The company can be reached via phone at (908) 428-9136 or via email at [email protected].